Skip to main content
. Author manuscript; available in PMC: 2015 Nov 6.
Published in final edited form as: Mol Cancer Res. 2014 Apr 25;12(7):979–986. doi: 10.1158/1541-7786.MCR-14-0158-T

Figure 4. BRAFV600E and PI3’-kinase signaling cooperate for human thyroid cancer cell proliferation and regulation of phospho-rpS6 and 4E-BP1.

Figure 4

A: 8505c (BRAFV600E/PIK3CAWT) and Ocut2 (BRAFV600E/PIK3CAH1047R) human anaplastic thyroid cancer cells were treated with an inhibitor of MEK1/2 (PD325901, 1μM, PD) or class 1 PI3’-kinases (GDC-0941, 2.5μM, GDC) either alone or in combination for 5 days at which time the cells were fixed and stained with Crystal Violet.

B&C: 8505c (BRAFV600E/PIK3CAWT) and Ocut2 (BRAFV600E/PIK3CAH1047R) human ATC cells were treated with an inhibitor of MEK1/2 (PD325901, 1μM, PD) or class 1 PI3’-kinases (GDC-0941, 2.5μM GDC) either alone or in combination for either 4 (B) or 24 (C) hours at which time the cells were lysed and protein expression/phosphorylation assessed by immunoblotting as indicated.